Fast triage of chest pain patients

ADVIA Centaur High-Sensitivity Troponin I Assay

The ADVIA Centaur® High-Sensitivity Troponin I (TNIH) assay* is the latest addition to Siemens Healthineers’ comprehensive cardiac menu to assist clinicians with the diagnosis and treatment of chest pain patients. Designed to aid in diagnosing acute myocardial infarctions (AMI) through the quantitative measurement of cardiac troponin I in serum or plasma, high-sensitivity troponin plays a critical role in the timely diagnosis of AMI, or heart attacks.

ADVIA Centaur High-Sensitivity Troponin I assay – Accurate results you can...
ADVIA Centaur High-Sensitivity Troponin I assay – Accurate results you can trust for fast triage of chest pain patients.
Source: Siemens Healthineers
The ADVIA Centaur High-Sensitivity Troponin I assay.
The ADVIA Centaur High-Sensitivity Troponin I assay.
Source: Siemens Healthineers

The ADVIA Centaur® High-Sensitivity Troponin I (TNIH) assay* is the latest addition to Siemens Healthineers’ comprehensive cardiac menu to assist clinicians with the diagnosis and treatment of chest pain patients. Designed to aid in diagnosing acute myocardial infarctions (AMI) through the quantitative measurement of cardiac troponin I in serum or plasma, high-sensitivity troponin plays a critical role in the timely diagnosis of AMI, or heart attacks.

The ADVIA Centaur® High-Sensitivity Troponin I assay is a true high-sensitivity assay:

  • Offers improved cardiac patient care with a high-sensitivity troponin assay that meets current European Society of Cardiology clinical guidelines
  • Provides fast, accurate and actionable test results allow clinicians to confidently rule in/rule out a myocardial infarction when triaging patients with chest pain
  • Ensures reliable results from a proven, trusted technology coupled with three new monoclonal antibodies

Compared to traditional troponin assays, the Siemens Healthineers ADVIA Centaur TNIH assay is able to detect lower levels of troponin and smaller changes to a patient’s troponin levels, which may be an early indication of AMI. This design affords clinicians greater confidence in patient results at the low end of the assay range by delivering precision that provides the ability to measure slight, yet critical, changes between serial troponin I values.

Precision at the low end is important to minimize analytic variation that could confuse a clinician’s assessment of a clinically significant change. With this data in hand, clinicians have the ability to more quickly diagnose and treat patients with suspected AMI, in some cases in as little as one to three hours.

Click here to learn more

*Not available for sale in the U.S.

 

Source: Siemens Healthineers

01.07.2017

Read all latest stories

Related articles

Photo

Sponsored • Earlier disease prediction and identification

The potential of AI in routine blood testing

It’s widely known that more than 70% of today’s medical decisions involve the results of laboratory tests, but the insights clinicians derive from these tests today may only be scratching the…

Photo

Sponsored • Siemens Naeotom Alpha

First CT scanner with photon-counting technology

Conventional CT imaging has reached its technical limitations: Resolution can only be improved by small margins and dose cannot be reduced significantly: Photon-counting technology enables drastic…

Photo

Sponsored • Photon-counting CT scanner

No detours, more detail

For the Siemens Healthineers team developing new and ever higher performing computed tomographs is daily fare. But when they introduced their most recent CT system an unusual sense of pride was…

Related products

Subscribe to Newsletter